Journal
BRITISH JOURNAL OF DERMATOLOGY
Volume 186, Issue 3, Pages 544-552Publisher
WILEY
DOI: 10.1111/bjd.20831
Keywords
-
Categories
Funding
- Regional Health Board South East
- Norwegian Research Council
- Oslo University Hospital
- The University of Oslo
- Health and Rehabilitation Norway
- The Foundation for Healthcare and Allergy Research in Sweden -Vardalstiftelsen
- The Swedish Asthma and Allergy Association's Research Foundation
- The Swedish Research Council -the Initiative for Clinical Therapy Research
- The Swedish Heart-Lung Foundation
- SFO-V Karolinska Institutet
- Ostfold Hospital Trust
- The European Union (MeDALL project)
- Norwegian Association of Asthma and Allergy
- The Kloster Foundation, Thermo Fisher, Uppsala, Sweden
- Furst Medical Laboratory, Oslo, Norway
- The Norwegian Society of Dermatology and Venerology
- Arne Ingel's legat
- Region Stockholm (ALF-project)
- Forte
- Swedish Order of Freemasons Foundation Barnhuset
- The Sven Jerring Foundation
- The Hesselman Foundation
- The Magnus Bergwall Foundation
- The Konsul Th C Bergh's Foundation
- The Swedish Society of Medicine
- The King Gustaf V 80th Birthday Foundation
- KI grants
- The Cancer and Allergy Foundation
- The Pediatric Research Foundation at Astrid Lindgren Children's Hospital
- The Samariten Foundation for Pediatric research
Ask authors/readers for more resources
In this study, FLG gene mutations were found to be associated with eczema and dry skin in infancy, but not with impaired skin barrier function or dry skin in general at 3 months of age.
Background Loss-of-function mutations in the skin barrier gene filaggrin (FLG) increase the risk of atopic dermatitis (AD), but their role in skin barrier function, dry skin and eczema in infancy is unclear. Objectives To determine the role of FLG mutations in impaired skin barrier function, dry skin, eczema and AD at 3 months of age and throughout infancy. Methods FLG mutations were analysed in 1836 infants in the Scandinavian population-based PreventADALL study. Transepidermal water loss (TEWL), dry skin, eczema and AD were assessed at 3, 6 and 12 months of age. Results FLG mutations were observed in 166 (9%) infants. At 3 months, carrying FLG mutations was not associated with impaired skin barrier function (TEWL > 11 center dot 3 g m(-2) h(-1)) or dry skin, but was associated with eczema [odds ratio (OR) 2 center dot 89, 95% confidence interval (CI) 1 center dot 95-4 center dot 28; P < 0 center dot 001]. At 6 months, mutation carriers had significantly higher TEWL than nonmutation carriers [mean 9 center dot 68 (95% CI 8 center dot 69-10 center dot 68) vs. 8 center dot 24 (95% CI 7 center dot 97-8 center dot 15), P < 0 center dot 01], and at 3 and 6 months mutation carriers had an increased risk of dry skin on the trunk (OR 1 center dot 87, 95% CI 1 center dot 25-2 center dot 80; P = 0 center dot 002 and OR 2 center dot 44, 95% CI 1 center dot 51-3 center dot 95; P < 0 center dot 001) or extensor limb surfaces (OR 1 center dot 52, 95% CI 1 center dot 04-2 center dot 22; P = 0 center dot 028 and OR 1 center dot 74, 95% CI 1 center dot 17-2 center dot 57; P = 0 center dot 005). FLG mutations were associated with eczema and AD in infancy. Conclusions FLG mutations were not associated with impaired skin barrier function or dry skin in general at 3 months of age, but increased the risk for eczema, and for dry skin on the trunk and extensor limb surfaces at 3 and 6 months.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available